Genital Wart Clinical Trial
Official title:
Comparison Between Tuberculin Vaccine and Cryotherapy in the Treatment of Genital Wart Patients
Cutaneous and genital warts are common dermatological conditions caused by Human Papilloma Virus. Although it is a benign condition it causes disfigurement, has tendency to collect, can be transmitted to others, this makes adequate and timely treatment important, while many warts are resolve spontaneously over several years, most patients seek treatment because the warts are unsightly and often tender or painful.
Genital warts are highly contagious sexually transmitted diseases (STD) caused by infection
of Human Papilloma Virus and, as the most common STD in developed countries, can currently
be considered to be globally epidemic.
It is estimated that the frequency of Human Papilloma Virus infection among women in the
world ranges from 2% to 44%.
The conventional modalities in treatment of warts include destructive therapies such as
salicylic acid, trichloroacetic acid, cryotherapy, silver nitrate, phenol, cantharidin,
surgical interventions and laser, antiproliferative agents such as bleomycin, vitamin D
analogs, podophyllin, 5 fluorouracil and antiviral agents such as cidofovir and retinoids.
There are different mechanisms have been proposed for the resolution of warts with skin test
antigens such as mumps, candida, trichophyton both at the injected as well as distant sites.
Tuberculin:
Purified protein derivative or tuberculin stimulates the cell mediated immunity non
specifically by activating T helper 1 cells, Natural Killer cells, and cytokine production
an increase in interleukin-12 as a process in boosting the cell-mediated immunity
contributes to the mechanism of action.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT05518201 -
Evaluate the Safety and Immunogenicity of a 9-valent HPV Vaccine in Chinese Healthy Male Aged 9-45 Year-old
|
Phase 1 | |
| Completed |
NCT05372016 -
Evaluate the Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
|
Phase 3 | |
| Recruiting |
NCT05027776 -
Immunogenicity and Safety of Quadrivalent HPV Vaccine in Healthy Chinese Female Subjects Aged 9 to 19 Years
|
Phase 3 | |
| Active, not recruiting |
NCT05580341 -
Phase III Study Comparing the Immunogenicity of 9-valent HPV Recombinant Vaccine and Gardasil-9
|
Phase 3 | |
| Completed |
NCT03676101 -
Evaluate the Safety and Primary Immunogenicity of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
|
Phase 1 | |
| Recruiting |
NCT04895020 -
Immunobridging Study of 9-valent Human Papillomavirus Recombinant Vaccine in Chinese Females Aged 9 to 19 Years
|
Phase 3 | |
| Completed |
NCT04425291 -
Evaluate the Immunogenicity and Safety of 4-valent and 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
|
Phase 3 | |
| Recruiting |
NCT05371353 -
Immune Persistence After the Whole Vaccination Shcedule With Recombination Quadrivalent HPV Vaccine
|
||
| Active, not recruiting |
NCT04073082 -
Safety and Efficacy of Laser Therapy in Gynaecology
|
||
| Completed |
NCT00999986 -
Low Dose Cyclophosphamide Treats Genital Warts
|
Phase 3 | |
| Terminated |
NCT05584332 -
A Phase Ⅲ Study to Evaluate the Efficacy, Immunogenicity, Safety of Quadrivalent HPV Recombinant Vaccine in Chinese Healthy Females
|
Phase 3 | |
| Completed |
NCT04796090 -
Genital Wart and Sexuality in Adolescence
|
||
| Enrolling by invitation |
NCT04905030 -
Education, Immigration and HPV Vaccination: an Informational Randomized Trial
|
N/A | |
| Recruiting |
NCT04422366 -
Evaluate the Efficacy, Immunogenicity and Safety of 9-valent HPV Recombinant Vaccine in Chinese Healthy Females
|
Phase 3 |